SSWIB manages and invests Wisconsin’s public employee retirement funds and other state assets for residents. It makes long-term investments across asset classes using internal research, risk controls, and external managers to build diversified portfolios aligned with actuarial targets while controlling costs. As a state agency, it emphasizes fiduciary duty, prudent stewardship, transparency, and long-horizon investing, combining public accountability with scale and expertise. Its goal is to maximize long-term returns for Wisconsin’s public retirement systems while controlling risk and costs to ensure funding stability for beneficiaries.
Work here?Claim your company
Industries
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Madison, WI
Founded
1951
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Elephas Biosciences raised $40M in a Series B-2 funding round to accelerate the commercialization of its Elephas Live™ Platform, a live tumor profiling technology for predicting immunotherapy responses. The funding, supported by existing investors like Northpond Ventures and ARCH Venture Partners, will aid in launching the platform as a laboratory developed test in 2026. CEO Maneesh Arora highlighted the strong investor confidence and the company's progress towards improving cancer treatment.
Company advancing novel live tumor imaging diagnostic platformMADISON, Wis., Jan. 23, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $55 million in Series C funding. Venture Investors Health Fund and State of Wisconsin Investment Board (SWIB) led the round. Continuing investments were made by Northpond Ventures, ARCH Ventures, Sands Capital, Moore Strategic Ventures, Tao Invest, and WARF Ventures. With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.Elephas is developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic imaging. The platform utilizes live patient biopsies with intact native tumor architecture and treats them with potential therapies to predict response to treatment
/PRNewswire/ -- HistoSonics, Inc. (www.histosonics.com), the developer of a non-invasive, novel sonic beam therapy, announced today that it has raised $85...
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Madison, WI
Founded
1951
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs